GRA BLOG
July 16, 2024
Forever, one of us
All of us at GRA are heartbroken by the loss of Lee Herron, who died July 12 after fighting health issues on several fronts.
From the day he joined GRA in 2008 until his retirement early this year, Lee personified our very mission of driving greater impact out of university research and entrepreneurship. His unique alchemy of acumen, insight and realism helped hundreds of researchers turn their discoveries into products and companies.
Personally, Lee was courageous beyond measure.
July 12, 2024
High-tech for the win
Georgia’s investment in university labs creates a major competitive advantage
State-of-the-art technology in Georgia’s university labs does more than speed discovery and invention. It also makes the state more competitive in landing multi-million research grants.
Since its founding in 1990, GRA has strategically invested in research instruments and core facilities. This investment has helped to:
Recruit top scientists to Georgia universities. Adding a key piece of equipment can immediately strengthen a researcher’s program and become a deciding factor for a major recruit.September 27, 2023
Georgia Research Alliance Trustees Name New President and CEO
Tim Denning, Ph.D. will succeed retiring Susan Shows in November
The Trustees of the Georgia Research Alliance voted today to appoint Timothy Denning, Ph.D., vice president for research and economic development at Georgia State University, as the fifth president and CEO of GRA. He will take the reins from Susan Shows, who announced her retirement in a planned succession after serving GRA since 2001 and as president and CEO since September 2020.
Denning, who will take the helm of the Alliance November 1, has led research and commercialization through a period of historic growth at Georgia State. Last month, the university announced it had earned just under $225 million in research funding for FY2023, the highest total in university history.
The university now has more than 70 research centers, including five university-level enterprises that address critical quality-of-life issues such as cancer, cardiovascular disease, brain health and infectious disease.
